Older adults · New York
Studies for adults 50 and older in New York
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
72 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Buffalo, NY + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- New York, NY + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Amherst, NY + 52 other US sites
- Eligibility basics
- Ages 50–85
- Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
RxFunction Inc.
- Location
- Amherst, NY + 3 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd.
- Location
- Hauppauge, NY + 66 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Liverpool, NY + 44 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- New York, NY + 32 other US sites
- Eligibility basics
- Ages 55–90
- Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
- Location
- Syosset, NY + 10 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Commack, NY + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Commack, NY + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Liverpool, NY + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- New Windsor, NY + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Liverpool, NY + 55 other US sites
- Eligibility basics
- Ages 55+
- Recruiting
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
MMI (Medical Microinstruments, Inc.)
- Location
- Buffalo, NY + 2 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Woodmere, NY + 7 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Exciva GmbH
- Location
- Brooklyn, NY + 6 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Great Neck, NY + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Albany, NY + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Great Neck, NY + 77 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Novartis Pharmaceuticals
- Location
- Albany, NY + 29 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 2
Open-label Extension Study in Participants With Early Alzheimer's Disease
GlaxoSmithKline
- Location
- Staten Island, NY + 8 other US sites
- Eligibility basics
- Ages 50–85
- Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Edwards Lifesciences
- Location
- Buffalo, NY + 49 other US sites
- Eligibility basics
- Ages 65+
- Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
EnCompass Technologies, Inc.
- Location
- New York, NY + 4 other US sites
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteers
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
- Location
- Rochester, NY + 9 other US sites
- Eligibility basics
- Ages 50–74 · Women only